This drug demonstrated significant efficacy in clinical trials, particularly showing a positive response in NSCLC patients with EGFR mutations, specifically those who acquired T790M mutations after prior treatment with initial or second-generation EGFR inhibitors [37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.